Context Therapeutics Inc. (CNTX)
| Market Cap | 134.14M +115.8% |
| Revenue (ttm) | n/a |
| Net Income | -40.23M |
| EPS | -0.42 |
| Shares Out | 91.88M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 288,315 |
| Open | 1.500 |
| Previous Close | 1.520 |
| Day's Range | 1.460 - 1.590 |
| 52-Week Range | 0.560 - 3.620 |
| Beta | 1.61 |
| Analysts | Strong Buy |
| Price Target | 6.00 (+310.96%) |
| Earnings Date | May 6, 2026 |
About CNTX
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company’s product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Penn... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for CNTX stock is "Strong Buy." The 12-month stock price target is $6.0, which is an increase of 310.96% from the latest price.
News
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
PHILADELPHIA, June 09, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific a...
Context Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
Three T-cell engager programs are advancing for solid tumors, with the lead Claudin 6 candidate showing promising early efficacy and safety in ovarian cancer. Combination strategies with ADCs and PD-1/VEGF inhibitors are planned, and key data updates are expected in the coming months.
Context Therapeutics to Present at the Jefferies Global Healthcare Conference
PHILADELPHIA, May 27, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific an...
Context Therapeutics enters license agreement amendment with BioAtla
Context Therapeutics (CNTX) announced the amendment of the company’s exclusive license agreement, dated September 23, 2024, with BioAtla (BCAB). The amendment removes all future milestone and royalty ...
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202
Context announces buyout of CT-202 future milestones and royalties in exchange for a fully paid-up, non-terminable license
Context Therapeutics reports Q1 EPS (9c), consensus (12c)
Cash and cash equivalents were $54.5M at March 31, 2026, compared to $66.0M at December 31, 2025. The company expects its cash and cash equivalents will be sufficient to fund…
Context Therapeutics Reports First Quarter 2026 Operating and Financial Results
Phase 1a interim data for ongoing CTIM-76 (CLDN6 x CD3) trial expected in June 2026 Phase 1a interim data for ongoing CT-95 (MSLN x CD3) trial expected in September 2026 Phase 1 initiation for CT-202 ...
Context Therapeutics Quarterly report: Q1 2026
Context Therapeutics has published its Q1 2026 quarterly earnings report on May 6, 2026.
Context Therapeutics Earnings release: Q1 2026
Context Therapeutics released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
Context Therapeutics Proxy statement: Proxy filing
Context Therapeutics filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Context Therapeutics Proxy statement: Proxy filing
Context Therapeutics filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Context Therapeutics Proxy statement: Proxy filing
Context Therapeutics filed a proxy statement on April 17, 2026, providing details for shareholder voting and corporate governance matters.
Context Therapeutics granted Fast Track Designation to CTIM-76 by FDA
Context Therapeutics (CNTX) announced that the FDA has granted Fast Track Designation to CTIM-76, a CLDN6 x CD3 T cell engaging bispecific antibody, for the treatment of platinum-resistant ovarian can...
Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer
Fast Track Designation highlights potential of CTIM-76 to address unmet need for patients with PROC CTIM-76 Phase 1a trial ongoing, with interim data expected in June 2026 PHILADELPHIA, April 02, 2026...
Context Therapeutics price target raised to $7 from $4 at Piper Sandler
Piper Sandler raised the firm’s price target on Context Therapeutics (CNTX) to $7 from $4 and keeps an Overweight rating on the shares after the company reported Q4/FY25 earnings and…
Context Therapeutics Reports Full Year 2025 Operating and Financial Results
Phase 1a interim data for ongoing trial of CTIM-76 (CLDN6 x CD3) expected in June 2026 Phase 1a interim data for ongoing trial of CT-95 (MSLN x CD3) expected in September 2026 Cash and cash equivalent...
Context Therapeutics Earnings release: Q4 2025
Context Therapeutics released its Q4 2025 earnings on March 23, 2026, summarizing the period's financial results.
Context Therapeutics Annual report: Q4 2025
Context Therapeutics has published its Q4 2025 annual report on March 23, 2026.
Context Therapeutics Slides: Corporate presentation
Context Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on March 23, 2026.
Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026
PHILADELPHIA, March 19, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bis...
Context Therapeutics Transcript: Leerink Global Healthcare Conference 2026
The discussion highlighted a robust pipeline of T-cell engagers targeting claudin 6, mesothelin, and nectin-4, with a focus on overcoming ADC resistance in solid tumors. Key data readouts are expected this year, with strategic moves toward less frequent dosing, outpatient administration, and combination therapies.
Context Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
Three T-cell engager programs are advancing in solid tumors, with Claudin 6 phase I data due Q2 and mesothelin data mid-2026. Innovations in antibody engineering aim to improve safety and efficacy, while strong financing supports ongoing clinical milestones.
Context Therapeutics to Participate in Upcoming Investor Conferences
PHILADELPHIA, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific a...
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PHILADELPHIA, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific a...
Context Therapeutics initiated with a Buy at JonesResearch
JonesResearch initiated coverage of Context Therapeutics (CNTX) with a Buy rating and $7 price target based on the firm’s view of the company’s “promising” pipeline of T cell engagers targeting…